Oxford's Churchill Hospital Cancer Centre — part of Oxford University Hospitals — is a major UK haematology centre managing CML and GIST patients requiring long-term Imatinib therapy. Generic Imatib provides Oxford patients with affordable access that matches the clinical standard of brand Glivec.
Oxford's research-active haematology environment means patients here often benefit from cutting-edge monitoring protocols, including regular BCR-ABL molecular testing that guides treatment duration decisions. For international patients treated at Oxford's private hospital sector, generic Imatib provides significant cost savings over UK branded pricing.
Visit medshopy.com or WhatsApp +91 82650 41513.
Oxford's research-active haematology environment means patients here often benefit from cutting-edge monitoring protocols, including regular BCR-ABL molecular testing that guides treatment duration decisions. For international patients treated at Oxford's private hospital sector, generic Imatib provides significant cost savings over UK branded pricing.
Visit medshopy.com or WhatsApp +91 82650 41513.
What does "treatment-free remission" mean in CML, and can patients on Imatib achieve it?Treatment-free remission (TFR) refers to the ability to stop CML treatment while maintaining undetectable BCR-ABL levels — effectively keeping the leukaemia suppressed without continued medication. Studies show that carefully selected patients who have achieved sustained deep molecular remission (MR4 or MR4.5) for at least 2-3 years can attempt stopping treatment under close molecular monitoring. Around 40-50% of such patients maintain remission off therapy. Those who relapse can restart Imatib and almost always regain remission. TFR is an active area of CML research and may be discussed with your Oxford haematologist if you have maintained a deep response for several years.